GO
Loading...

Takeover Bids

More

  • BRUSSELS/ FRANKFURT, July 2- European regulators have cleared Telefonica's bid to consolidate the German mobile market by buying smaller rival KPN's E-Plus for 8.6 billion euros, raising prospects of more deals to come across Europe's telecoms markets.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • June 30- Home healthcare service provider Gentiva Health Services Inc said its board had rejected an unsolicited offer from Kindred Healthcare Inc, saying the offer significantly undervalued the company.

  • CNBC's David Faber provides insight to AbbVie's $46 billion case to take over Shire.

  • *Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.

  • *Syngenta declines to comment on report of Monsanto talks. ZURICH, June 24- Syngenta's shares jumped on Tuesday after a media report that the Swiss crop chemical maker had been in talks about a $40 billion takeover by U.S. rival Monsanto Co to create the world's largest agrochemical company.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • June 23- Augusta Resource Corp said it agreed to be bought by HudBay Minerals Inc after the company raised its offer to buy Augusta shares it does not already own. The offer price of about C $3.56 per Augusta common share represents a premium of about 11 percent to Augusta's Friday close on the Toronto Stock Exchange.

  • Augusta agrees to revised HudBay takeover offer Monday, 23 Jun 2014 | 7:10 AM ET

    June 23- Augusta Resource Corp said it agreed to be bought by HudBay Minerals Inc after the company raised its offer to buy Augusta shares it does not already own. The revised offer values Augusta at about C $555 million, HudBay said.

  • LONDON, June 20- The FTSEurofirst 300 climbed to a 6-1/ 2- year high on Friday and recorded its 10th straight week of gains, with analysts saying that expectations of a pick-up in merger and acquisition activity will further boost sentiment.

  • Cramer: AbbVie-Shire driven by inversion     Friday, 20 Jun 2014 | 9:07 AM ET

    British drug maker Shire has rejected a $46 billion takeover offer from U.S. based AbbVie. CNBC's Jim Cramer discusses the latest attempt by a U.S. health care company to tap into the low foreign tax rate.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- The pan-European FTSEurofirst 300 index reached a 6 1/ 2- year high on Friday as the drugmaker Shire rallied on a takeover offer, putting the index on track for a 10th straight week of gains. Shire climbed 11.4 percent to 41.65 pounds after AbbVie confirmed it had made an offer to acquire it.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • Shire props up European shares on bid hopes Friday, 20 Jun 2014 | 3:56 AM ET

    *Shire up 13 percent as AbbVie confirms rejected bid. LONDON, June 20- A rally in drugmaker Shire helped European bourses hold onto gains on Friday on news the British firm had been the target of a takeover bid from U.S. rival AbbVie. Shares in Shire rose 13 percent to 42.31 pounds after AbbVie confirmed it had made a bid approach, which was rejected by Shire's board.

  • LONDON, June 20- British drugmaker Shire has rejected a takeover offer from AbbVie Inc which would have valued the group at around 27 billion pounds, the U.S. firm said on Friday.

  • *U.S. group says alliance proposal agreed with Alstom management. PARIS, June 19- U.S. conglomerate General Electric reshaped its offer for the power assets of Alstom on Thursday to propose an alliance based on 50:50 joint ventures that would ringfence sensitive nuclear activities.

  • SYDNEY/ JOHANNESBURG, June 19- Australian retailer David Jones Ltd has postponed a shareholder vote on a $2 billion takeover bid from South Africa's Woolworths after Australian billionaire Solomon Lew amassed a stake that could scupper the deal.